Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>CLSA Reiterates Outperform on TIGERMED w/ TP Raised to HKD57.2
Recommend 1 Positive 2 Negative 0 |
||||
|
||||
|
CLSA said in its research report that 2026 will be a turning point for China's biotechnology industry. Maintaining TIGERMED (03347.HK) as its top choice for investing in China's innovative drugs, it has raised its target price for the drugmaker from HKD52.1 to HKD57.2 and reiterated an Outperform rating. Looking ahead to 2026, CLSA believes the sector will show two major development directions. The Chinese clinical CRO industry, after consolidation, will reach a turning point with more reasonable pricing driving the recovery of industry margins, while the strengthening of the H-share innovative drug sector will support the exit performance of TIGERMED's investment portfolio projects. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
